单位:[1]Department of Pulmonary and Critical Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100069, China首都医科大学宣武医院[2]Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York 10001, USA[3]Department of Pulmonary and Critical Care Medicine, China‑Japan Friendship Hospital, Beijing 100029, China
Objective: The development of culture-independent techniques for microbiological analysis shows that bronchial tree is not sterile in either healthy or chronic obstructive pulmonary disease (COPD) individuals. With the advance of sequencing technologies, lung microbiome has become a new frontier for pulmonary disease research, and such advance has led to better understanding of the lung microbiome in COPD. This review aimed to summarize the recent advances in lung microbiome, its relationships with COPD, and the possible mechanisms that microbiome contributed to COPD pathogenesis. Data Sources: Literature search was conducted using PubMed to collect all available studies concerning lung microbiome in COPD. The search terms were "microbiome" and "chronic obstructive pulmonary disease", or "microbiome" and "lung/pulmonary". Study Selection: The papers in English about lung microbiome or lung microbiome in COPD were selected, and the type of articles was not limited. Results: The lung is a complex microbial ecosystem; the microbiome in lung is a collection of viable and nonviable microbiota (bacteria, viruses, and fungi) residing in the bronchial tree and parenchymal tissues, which is important for health. The following types of respiratory samples are often used to detect the lung microbiome: sputum, bronchial aspirate, bronchoalveolar lavage, and bronchial mucosa. Disordered bacterial microbiome is participated in pathogenesis of COPD; there are also dynamic changes in microbiota during COPD exacerbations. Lung microbiome may contribute to the pathogenesis of COPD by manipulating inflammatory and/or immune process. Conclusions: Normal lung microbiome could be useful for prophylactic or therapeutic management in COPD, and the changes of lung microbiome could also serve as biomarkers for the evaluation of COPD.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81400039, 91643115]; Foundation of Chinese Ministry of Science and Technology [2016YFC0206502, 2016YFC1303900, 2016YFC0901102]; National Natural Science Foundation of BeijingBeijing Natural Science Foundation [Z16000]
第一作者单位:[1]Department of Pulmonary and Critical Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100069, China
通讯作者:
通讯机构:[3]Department of Pulmonary and Critical Care Medicine, China‑Japan Friendship Hospital, Beijing 100029, China[*1]Department of Pulmonary and Critical Care Medicine, China‑Japan Friendship Hospital, 2 Yinghua Dongjie, Chaoyang District, Beijing 100029, China
推荐引用方式(GB/T 7714):
Wang Lei,Hao Ke,Yang Ting,et al.Role of the Lung Microbiome in the Pathogenesis of Chronic Obstructive Pulmonary Disease[J].CHINESE MEDICAL JOURNAL.2017,130(17):2107-2111.doi:10.4103/0366-6999.211452.
APA:
Wang, Lei,Hao, Ke,Yang, Ting&Wang, Chen.(2017).Role of the Lung Microbiome in the Pathogenesis of Chronic Obstructive Pulmonary Disease.CHINESE MEDICAL JOURNAL,130,(17)
MLA:
Wang, Lei,et al."Role of the Lung Microbiome in the Pathogenesis of Chronic Obstructive Pulmonary Disease".CHINESE MEDICAL JOURNAL 130..17(2017):2107-2111